HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 01/29/2013 -- Georgia Gulf Corp. (NYSE:GGC) is now officially Axiall Corp. with the Monday completion of its $2 billion acquisition of PPG Industries Inc.’s chlor-alkali and derivatives business. It starts trading under the new stock symbol “AXLL” on Jan. 29. The Atlanta-based chemicals and building products company also added Victoria Haynes, Michael McGarry and Robert Ripp to its board of directors. Haynes has been a director of PPG Industries since 2003. Ripp has been a director of PPG Industries since 2003. McGarry became executive vice president of PPG Industries Inc. in 2012.
Should Investor Book Profit and Exit From GGC: Need Instant Reply Check Here
Meritor (NYSE:MTOR) is expected to report Q1 earnings on Jan. 30. Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Meritor's revenues will contract -19.0% and EPS will compress -66.7%. The average estimate for revenue is $939.3 million. On the bottom line, the average EPS estimate is $0.04. Last quarter, Meritor booked revenue of $986.0 million. GAAP reported sales were 19% lower than the prior-year quarter's $1.22 billiON. Last quarter, non-GAAP EPS came in at $0.32. GAAP EPS of $0.05 for Q4 were 84% lower than the prior-year quarter's $0.32 per share.
Is MTOR A Secure Investment? Watch Out An Over View of MTOR Here
Velti (NASDAQ:VELT), the leading global provider of mobile marketing and advertising technology, today announced that it will webcast its 2013 Analyst Day event on Jan. 30, 2013, beginning at 8:30 a.m. ET. The event will run until approximately 2:00 pm ET and the webcast will be available in the investor relations section of company’s website at www.velti.com under Events and Presentations.
Is VELT Going To Move Higher As Many Investors Expect: Find Out Here
Shares of medical isotope supplier Nordion (NYSE:NDZ) shot higher by as much as 15% after reporting its fourth-quarter earnings results and announcing the start of a strategic review that could end in a sale of the company. For the quarter, Nordion recorded a one-time laden loss of $0.70 per share as revenue remained flat at $74.7 million. Adjusted for one-time costs, the company earned a profit of $0.34, up 13% from last year, but also cautioned that isotope sales are expected to dip 20% this year. The big news was Nordion's hiring of Jefferies to help with its strategic review -- a fancy phrase for, "Can we sell this company to increase shareholder value?" The reason for doing this relates to a lawsuit it lost in September that would have recouped damages from its main isotope supplier, the Atomic Energy of Canada, or ACEL. ACEL provides Nordion with molybdenum-99, a medical imaging isotope, and beyond contracts that expire in 2016, Nordion's supply of this isotope and its operations in general, are very much up in the air.
Should Investor Hold NDZ For The Next Big Move: Check Out Recent Analyst View
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)